BIAL R&D Investments

BIAL is an international pharmaceutical company headquartered in Portugal, dedicated to the discovery, development, and commercialization of innovative therapeutic solutions. The company focuses primarily on the Central Nervous System (CNS), with a strong track record in neurology, particularly in Parkinson's disease and epilepsy. BIAL's R&D efforts have successfully brought proprietary drugs to market, including eslicarbazepine acetate and opicapone. The company maintains a global presence, distributing its products in over 50 countries and reinvesting a significant portion of its turnover into research and development to address unmet medical needs.